挪威医护人员接种AZD1222后血小板减少及抗PF4/聚阴离子抗体流行率观察研究
多数受试者血小板计数正常且免疫检测阴性,仅6人检出无血小板活化特性的抗PF4/聚阴离子抗体(光密度≥0.4,范围0.58-1.16),均血小板正常,无人出现严重血小板减少。结论为接种后两者流行率均低。
要点
- 仅6人检出无血小板活化特性的抗PF4/聚阴离子抗体,均血小板正常。
- 无人出现严重血小板减少,支持该人群不良反应风险低。
核心结论
- 挪威医护人员接种AZD1222后血小板减少和抗PF4/聚阴离子复合物抗体的流行率均低。
主要发现
- 多数受试者血小板计数正常且PF4/PVS免疫检测阴性。
- 仅6人检出抗PF4/聚阴离子抗体(光密度≥0.4,范围0.58-1.16),均无血小板活化特性且血小板正常。
- 无受试者出现严重血小板减少。
关键数值与推荐
- 抗PF4/聚阴离子抗体阳性判定为光密度≥0.4,检出者光密度范围0.58-1.16。
临床怎么用
- 在接种AZD1222的健康人群中,血小板减少及抗PF4/聚阴离子抗体检测阳性率低,可辅助评估疫苗相关免疫性血栓性血小板减少的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 vaccine from AstraZeneca (AZD1222) is one of several vaccines introduced to provide immunity against SARS-CoV-2. Recently, more than 50 cases have been reported presenting a combination of thrombosis, thrombocytopenia, and remarkably high levels of anti-platelet factor 4 (PF4)/polyanion antibodies post-AZD1222 vaccination. Now linked to the vaccine, the condition is referred to as vaccine-induced immune thrombotic thrombocytopenia. The European Medicines Agency still recommends vaccination with AZD1222, but several European countries have temporally paused and/or restricted its use because of the perceived risk of this severe side effect. Because there is no description of PF4/polyanion antibody testing in the clinical trials, knowledge about the prevalence of such antibodies in a vaccinated cohort is needed. OBJECTIVES: To investigate prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in a population recently vaccinated with AZD1222. PATIENTS/METHODS: Four hundred and ninety-two health care workers recently vaccinated with the first dose of AZD1222 were recruited from two hospitals in Norway. Study individuals were screened for thrombocytopenia and the presence of anti-PF4/polyanion antibodies with a PF4/PVS immunoassay. Side effects after vaccination were registered. RESULTS: The majority of study participants had normal platelet counts and negative immunoassay. Anti-PF4/polyanion antibodies without platelet activating properties were only detected in six individuals (optical density ≥0.4, range 0.58-1.16), all with normal platelet counts. No subjects had severe thrombocytopenia. CONCLUSIONS: We found low prevalence of both thrombocytopenia and antibodies to PF4/polyanion-complexes among Norwegian health care workers after vaccination with AZD1222.
引用
- Sørvoll IH, Horvei KD, Ernstsen SL, et al. An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. J Thromb Haemost. 2021. PMID: 33909350. doi:10.1111/jth.15352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。